PHS
ATXS

PFM Health Sciences’s Astria Therapeutics ATXS Stock Holding History

PFM Health Sciences’s Portfolio ATXS Stock Details ATXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-327,045
Closed -$4.6M – 81
2024
Q1 		$4.6M Buy
+327,045
New +$4.07M 0.22% 70

Other funds holding ATXS

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

PFM Health Sciences's ATXS Position: Q2 2024 in Review

PFM Health Sciences sold out of Astria Therapeutics (ATXS) in Q2 2024, closing a stake of 327,045 shares — an estimated $4.6M sold.

PFM Health Sciences first reported a position in ATXS in Q1 2024 and held it in 1 quarter. The position peaked at $4.6M in Q1 2024. 100 funds tracked by Wall St. Rank hold ATXS as of Q2 2024.

  • PFM Health Sciences reported no remaining Astria Therapeutics position as of Q2 2024 after selling out during the quarter.
  • PFM Health Sciences sold 327,045 Astria Therapeutics shares in Q2 2024, an estimated $4.6M.
  • PFM Health Sciences first reported a position in Astria Therapeutics in Q1 2024 and held it in 1 quarter.
  • PFM Health Sciences's Astria Therapeutics position peaked at $4.6M in Q1 2024.
  • 100 funds tracked by Wall St. Rank held Astria Therapeutics as of Q2 2024.

Based on PFM Health Sciences's 13F filing for Q2 2024, filed 14 Aug 2024.